Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5538885 | 0.79 | HSD17B10 (0.59) | L3MBTL1MAPTALDH1A1IDO1TSHR | |
| SCHEMBL7443912 | 0.76 | L3MBTL1 (0.53) | L3MBTL1MAPTGAARAB9AALDH1A1 | |
| SCHEMBL3047149 | 0.76 | L3MBTL1 (0.53) | L3MBTL1MAPTGAARAB9AALDH1A1 | |
| SCHEMBL8557281 | 0.76 | L3MBTL1 (0.53) | L3MBTL1MAPTGAARAB9AALDH1A1 | |
| SCHEMBL6542650 | 0.76 | MAPT (0.69) | L3MBTL1MAPTGAARAB9AALDH1A1 | |
| SCHEMBL3910980 | 0.76 | L3MBTL1 (0.59) | L3MBTL1MAPTGAARAB9AALDH1A1 | |
| SCHEMBL4756063 | 0.76 | L3MBTL1 (0.53) | L3MBTL1MAPTGAARAB9AALDH1A1 | |
| SCHEMBL3907119 | 0.76 | L3MBTL1 (0.53) | L3MBTL1MAPTRAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL6032214 | 0.76 | L3MBTL1 (0.53) | L3MBTL1MAPTGAARAB9AALDH1A1 | |
| SCHEMBL7357539 | 0.75 | IDO1 (0.47) | MAPTADRA2AIDO1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018017221-A1 | METHOD TO EXTRACT BITUMEN FROM OIL SANDS USING AROMATIC AMINES | DOW GLOBAL TECHNOLOGIES LLC (US) | 2018-01-25 | — | — | WO | claimed |
| US-8828438-B2 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase | BEND RESEARCH, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| EP-2464647-A1 | AZAINDAZOLES AS BTK KINASE MODULATORS AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20120083490-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-04-05 | — | — | US | disclosed |
| WO-2011019780-A1 | AZAINDAZOLES AS BTK KINASE MODULATORS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-17 | — | — | WO | disclosed |
| EP-2081917-A2 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | Abbott Laboratories (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-2062054-A1 | USE OF LIPOCALIN 2 IN THE REGULATION OF INSULIN SENSITIVITY | Beth Israel Deaconess Medical Center, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20090118328-A1 | Pharmaceutical Compositions Of Cholesteryl Ester Transfer Protein Inhibitors And Hmg-Coa Reductase | BEND RESEARCH, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| EP-1846005-A4 | KITS AND IMPROVED COMPOSITIONS FOR TREATING LOWER URINARY TRACT | URIGEN INC (US) | 2008-12-10 | — | — | EP | disclosed |
| WO-2008030370-A9 | USE OF LIPOCALIN 2 IN THE REGULATION OF INSULIN SENSITIVITY | BETH ISRAEL HOSPITAL (US) | 2008-05-22 | — | — | WO | disclosed |
| EP-0600831-A1 | Phtalazinon derivatives | CIBA-GEIGY AG (CH) | 1994-06-08 | — | — | EP | disclosed |
| EP-0600832-A1 | Derivatives of diamino benzoic and diamino phthalic acid und their use as protein linase inhibitors | CIBA-GEIGY AG (CH) | 1994-06-08 | — | — | EP | disclosed |
| US-5246952-A | Antitumor agents | CIBA-GEIGY CORPORATION (US) | 1993-09-21 | — | — | US | disclosed |
| US-5227393-A | estrogen-dependent diseases, anticancer | CIBA-GEIGY CORPORATION (US) | 1993-07-13 | — | — | US | disclosed |
| EP-0516588-A1 | Substituted diaminophtalimides and analogues | CIBA-GEIGY AG (CH) | 1992-12-02 | — | — | EP | disclosed |
| EP-0477141-A1 | Heteroarylmethylbenzols aromatase inhibitors | CIBA-GEIGY AG (CH) | 1992-03-25 | — | — | EP | disclosed |
| US-5073574-A | TETRAZOLYL SUBSTITUTED BENZONITRILES AND ANTI-TUMOR USE THEREOF | CIBA-GEIGY CORPORATION (US) | 1991-12-17 | — | — | US | disclosed |
| EP-0457716-A1 | Naphthalin derivatives | CIBA-GEIGY AG (CH) | 1991-11-21 | — | — | EP | disclosed |
| EP-0445073-A1 | Benzofurans | CIBA-GEIGY AG (CH) | 1991-09-04 | — | — | EP | disclosed |
| EP-0408509-A2 | Substituted benzonitriles | CIBA-GEIGY AG (CH) | 1991-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083490-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | CYP3A43, CYP3A5, POR | L3MBTL1 4679/4885MAPT 2964/4885GAA 408/4885 |
| US-20090118328-A1 | Pharmaceutical Compositions Of Cholesteryl Ester Transfer Protein Inhibitors And Hmg-Coa Reductase | CETP, HMGCR, MTTP | L3MBTL1 4128/4885MAPT 547/4885GAA 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.